Maraviroc decreases CCL8-mediated migration of CCR5+ regulatory T cells and reduces metastatic tumor growth in the lungs

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Halvorsen, E C ^a,b   Hamilton, M J ^a   Young, A ^a,b   Wadsworth, B J ^a,b   LePard, N E ^a   Lee, H N ^a   Firmino, N ^a,b   Collier, J L ^a,b   Bennewith, K L ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Breast cancer; CCR5; Maraviroc; metastasis; Regulatory T cells

Indexed keywords

MARAVIROC;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER TRANSPLANTATION; CELL MIGRATION; CELL VIABILITY; CHEMOTAXIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; LUNG LAVAGE; LUNG METASTASIS; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR VOLUME;

EID: 84969690132     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1150398     Document Type: Article

References (63)

1. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28:3271-7; PMID:20498394; 10.1200/JCO.2009.25.9820 PMID:20498394
2. C.L.Zindl, D.D.Chaplin. Immunology. Tumor immune evasion. Science 2010; 328:697-8; PMID:20448171; 10.1126/science.1190310.
3. R.Kim, M.Emi, K.Tanabe, K.Arihiro. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006; 66:5527-36; PMID:16740684; 10.1158/0008-5472.CAN-05-4128
4. M.Meissner, T.E.Reichert, M.Kunkel, W.Gooding, T.L.Whiteside, S.Ferrone, B.Seliger. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 2005; 11:2552-60; PMID:15814633; 10.1158/1078-0432.CCR-04-2146
5. M.J.Hamilton, M.Bosiljcic, N.E.Lepard, E.C.Halvorsen, V.W.Ho, J.P.Banath, G.Krystal, K.L.Bennewith. Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas. J Immunol 2014; 192:512-22; PMID:24285836; 10.4049/jimmunol.1300096
6. J.I.Youn, D.I.Gabrilovich. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010; 40:2969-75; PMID:21061430; 10.1002/eji.201040895
7. S.Sakaguchi, N.Sakaguchi, M.Asano, M.Itoh, M.Toda. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64; PMID:7636184.
8. E.C.Halvorsen, S.M.Mahmoud, K.L.Bennewith. Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev 2014; 33:1025-41; PMID:25359584; 10.1007/s10555-014-9529-x
9. M.Beyer, J.L.Schultze. Regulatory T cells in cancer. Blood 2006; 108:804-11; PMID:16861339; 10.1182/blood-2006-02-002774
10. G.J.Bates, S.B.Fox, C.Han, R.D.Leek, J.F.Garcia, A.L.Harris, A.H.Banham. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373-80; PMID:17135638; 10.1200/JCO.2006.05.9584
11. F.Liu, R.Lang, J.Zhao, X.Zhang, G.A.Pringle, Y.Fan, D.Yin, F.Gu, Z.Yao et al. CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 2011; 130:645-55; PMID:21717105; 10.1007/s10549-011-1647-3
12. T.Yamaguchi, J.B.Wing, S.Sakaguchi. Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions. Semin Immunol 2011; 23:424-30; PMID:22055883; 10.1016/j.smim.2011.10.002
13. K.Wing, Y.Onishi, P.Prieto-Martin, T.Yamaguchi, M.Miyara, Z.Fehervari, T.Nomura, S.Sakaguchi. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322:271-5; PMID:18845758; 10.1126/science.1160062
14. L.Y.Chang, Y.C.Lin, C.W.Kang, C.Y.Hsu, Y.Y.Chu, C.T.Huang, Y.J.Day, T.C.Chen, C.T.Yeh et al. The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector/memory regulatory T cells. J Immunol 2012; 189:567-74; PMID:22664873; 10.4049/jimmunol.1200266
15. J.Duraiswamy, K.M.Kaluza, G.J.Freeman, G.Coukos. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013; 73:3591-603; PMID:23633484; 10.1158/0008-5472.CAN-12-4100
16. E.Elkord, M.Abd Al Samid, B.Chaudhary. Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP. Oncotarget 2015; 6:20026-36; PMID:26343373; 10.18632/oncotarget.4771
17. A.Facciabene, X.Peng, I.S.Hagemann, K.Balint, A.Barchetti, L.P.Wang, P.A.Gimotty, C.B.Gilks, P.Lal et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475:226-30; PMID:21753853; 10.1038/nature10169
18. W.Tan, W.Zhang, A.Strasner, S.Grivennikov, J.Q.Cheng, R.M.Hoffman, M.Karin. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470:548-53; PMID:21326202; 10.1038/nature09707
19. T.J.Curiel, G.Coukos, L.Zou, X.Alvarez, P.Cheng, P.Mottram, M.Evdemon-Hogan, J.R.Conejo-Garcia, L.Zhang et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; 10.1038/nm1093
20. A.Fialova, S.Partlova, L.Sojka, H.Hromadkova, T.Brtnicky, J.Fucikova, P.Kocian, L.Rob, J.Bartunkova et al. Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. Int J Cancer 2013; 132:1070-9; PMID:22865582; 10.1002/ijc.27759
21. M.Gobert, I.Treilleux, N.Bendriss-Vermare, T.Bachelot, S.Goddard-Leon, V.Arfi, C.Biota, A.C.Doffin, I.Durand et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009; 69:2000-9; PMID:19244125; 10.1158/0008-5472.CAN-08-2360
22. E.Schlecker, A.Stojanovic, C.Eisen, C.Quack, C.S.Falk, V.Umansky, A.Cerwenka. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 2012; 189:5602-11; PMID:23152559; 10.4049/jimmunol.1201018
23. M.C.Tan, P.S.Goedegebuure, B.A.Belt, B.Flaherty, N.Sankpal, W.E.Gillanders, T.J.Eberlein, C.S.Hsieh, D.C.Linehan. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009; 182:1746-55; PMID:19155524; 10.4049/jimmunol.182.3.1746
24. S.T.Ward, K.K.Li, E.Hepburn, C.J.Weston, S.M.Curbishley, G.M.Reynolds, R.K.Hejmadi, R.Bicknell, B.Eksteen et al. The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer. Br J Cancer 2015; 112:319-28; PMID:25405854; 10.1038/bjc.2014.572
25. E.Righi, S.Kashiwagi, J.Yuan, M.Santosuosso, P.Leblanc, R.Ingraham, B.Forbes, B.Edelblute, B.Collette et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 2011; 71:5522-34; PMID:21742774; 10.1158/0008-5472.CAN-10-3143
26. J.Blaszczyk, E.V.Coillie, P.Proost, J.V.Damme, G.Opdenakker, G.D.Bujacz, J.M.Wang, X.Ji. Complete crystal structure of monocyte chemotactic protein-2, a CC chemokine that interacts with multiple receptors. Biochemistry 2000; 39:14075-81; PMID:11087354; 10.1021/bi0009340
27. B.Haworth, H.Lin, M.Fidock, P.Dorr, P.G.Strange. Allosteric effects of antagonists on signalling by the chemokine receptor CCR5. Biochem Pharmacol 2007; 74:891-7; PMID:17669370; 10.1016/j.bcp.2007.06.032
28. A.Mueller, N.G.Mahmoud, M.C.Goedecke, J.A.McKeating, P.G.Strange. Pharmacological characterization of the chemokine receptor, CCR5. Br J Pharmacol 2002; 135:1033-43; PMID:11861332; 10.1038/sj.bjp.0704540
29. M.Mack, J.Cihak, C.Simonis, B.Luckow, A.E.Proudfoot, J.Plachy, H.Bruhl, M.Frink, H.J.Anders et al. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol 2001; 166:4697-704; PMID:11254730; 10.4049/jimmunol.166.7.4697
30. Y.Zhang, F.Y.Meng, W.L.Li, C.X.Zhou, Z.Guan, H.Y.Fan. Association of chemotactic factor receptor 5 gene with breast cancer. Genet Mol Res 2013; 12:5289-300; PMID:24301790; 10.4238/2013.November.7.4
31. N.J.Carter, G.M.Keating. Maraviroc. Drugs 2007; 67:2277-88; discussion 89–90; PMID:17927288; 10.2165/00003495-200767150-00010.
32. P.J.Kersey, J.E.Allen, M.Christensen, P.Davis, L.J.Falin, C.Grabmueller, D.S.Hughes, J.Humphrey, A.Kerhornou et al. Ensembl Genomes 2013: scaling up access to genome-wide data. Nucleic Acids Res 2014; 42:D546-52; PMID:24163254; 10.1093/nar/gkt979
33. E.A.Lynch, C.A.Heijens, N.F.Horst, D.M.Center, W.W.Cruikshank. Cutting edge: IL-16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. J Immunol 2003; 171:4965-8; PMID:14607889; 10.4049/jimmunol.171.10.4965
34. N.Ruffing, N.Sullivan, L.Sharmeen, J.Sodroski, L.Wu. CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells. Cell Immunol 1998; 189:160-8; PMID:9790730; 10.1006/cimm.1998.1379
35. J.Liu, N.Zhang, Q.Li, W.Zhang, F.Ke, Q.Leng, H.Wang, J.Chen. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One 2011; 6:e19495; PMID:21559338; 10.1371/journal.pone.0019495
36. I.Wertel, J.Surowka, G.Polak, B.Barczynski, W.Bednarek, J.Jakubowicz-Gil, A.Bojarska-Junak, J.Kotarski. Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients. Tumour Biol 2015; 36:4811-7; PMID:25647263; 10.1007/s13277-015-3133-8
37. M.R.Karta, M.L.Gavala, C.S.Curran, L.E.Wickert, P.J.Keely, J.E.Gern, P.J.Bertics. LPS modulates rhinovirus-induced chemokine secretion in monocytes and macrophages. Am J Respir Cell Mol Biol 2014; 51:125-34; PMID:24498897; 10.1165/rcmb.2013-0404OC
38. D.N.Kroetz, G.S.Deepe, Jr. An aberrant thymus in CCR5−/− mice is coupled with an enhanced adaptive immune response in fungal infection. J Immunol 2011; 186:5949-55; PMID:21478401; 10.4049/jimmunol.1003876
39. X.Tai, F.Van Laethem, L.Pobezinsky, T.Guinter, S.O.Sharrow, A.Adams, L.Granger, M.Kruhlak, T.Lindsten et al. Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood 2012; 119:5155-63; PMID:22403258; 10.1182/blood-2011-11-388918
40. S.L.Deshmane, S.Kremlev, S.Amini, B.E.Sawaya. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29:313-26; PMID:19441883; 10.1089/jir.2008.0027
41. B.Shang, Y.Liu, S.J.Jiang. Prognostic value of tumor-infiltrating FoxP3(+) regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 2015; 5:15179; PMID:26462617; 10.1038/srep15179
42. H.Tao, Y.Mimura, K.Aoe, S.Kobayashi, H.Yamamoto, E.Matsuda, K.Okabe, T.Matsumoto, K.Sugi et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer 2012; 75:95-101; PMID:21719142; 10.1016/j.lungcan.2011.06.002
43. W.L.Byrne, K.H.Mills, J.A.Lederer, G.C.O'Sullivan. Targeting regulatory T cells in cancer. Cancer Res 2011; 71:6915-20; PMID:22068034; 10.1158/0008-5472.CAN-11-1156
44. S.L.Hembruff, N.Cheng. Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting. Cancer Ther 2009; 7:254-67; PMID:20651940
45. U.K.Liyanage, T.T.Moore, H.G.Joo, Y.Tanaka, V.Herrmann, G.Doherty, J.A.Drebin, S.M.Strasberg, T.J.Eberlein et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-61; PMID:12193750; 10.4049/jimmunol.169.5.2756
46. A.Lal, L.Chan, S.Devries, K.Chin, G.K.Scott, C.C.Benz, Y.Y.Chen, F.M.Waldman, E.S.Hwang. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat 2013; 139:381-90; PMID:23712790; 10.1007/s10549-013-2556-4
47. M.Takenaka, N.Seki, U.Toh, S.Hattori, A.Kawahara, T.Yamaguchi, K.Koura, R.Takahashi, H.Otsuka et al. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol 2013; 1:625-32; PMID:24649219; 10.3892/mco.2013.107
48. G.H.Heppner, F.R.Miller, P.M.Shekhar. Nontransgenic models of breast cancer. Breast Cancer Res 2000; 2:331-4; PMID:11250725; 10.1186/bcr77
49. M.Parviz, C.S.Chin, L.J.Graham, C.Miller, C.Lee, K.George, H.D.Bear. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol Immunother 2003; 52:739-50; PMID:12827306; 10.1007/s00262-003-0405-8
50. K.S.Peggs, S.A.Quezada, C.A.Chambers, A.J.Korman, J.P.Allison. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206:1717-25; PMID:19581407; 10.1084/jem.20082492
51. D.C.Soler, H.Sugiyama, A.B.Young, J.V.Massari, T.S.McCormick, K.D.Cooper. Psoriasis patients exhibit impairment of the high potency CCR5(+) T regulatory cell subset. Clin Immunol 2013; 149:111-8; PMID:23954573; 10.1016/j.clim.2013.06.007
52. M.Velasco-Velazquez, R.G.Pestell. The CCL5/CCR5 axis promotes metastasis in basal breast cancer. Oncoimmunology 2013; 2:e23660; PMID:23734321; 10.4161/onci.23660
53. L.Y.Chang, Y.C.Lin, J.Mahalingam, C.T.Huang, T.W.Chen, C.W.Kang, H.M.Peng, Y.Y.Chu, J.M.Chiang et al. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res 2012; 72:1092-102; PMID:22282655; 10.1158/0008-5472.CAN-11-2493
54. J.T.Jordan, W.Sun, S.F.Hussain, G.DeAngulo, S.S.Prabhu, A.B.Heimberger. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 2008; 57:123-31; PMID:17522861; 10.1007/s00262-007-0336-x
55. L.Ochoa-Callejero, L.Perez-Martinez, S.Rubio-Mediavilla, J.A.Oteo, A.Martinez, J.R.Blanco. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS One 2013; 8:e53992; PMID:23326556; 10.1371/journal.pone.0053992
56. M.C.Rosario, P.Jacqmin, P.Dorr, I.James, T.M.Jenkins, S.Abel, E.van der Ryst. Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients. Br J Clin Pharmacol 2008; 65 Suppl 1:86-94; PMID:18333870; 10.1111/j.1365-2125.2008.03140.x
57. Y.Saita, M.Kondo, Y.Shimizu. Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol 2007; 7:1528-34; PMID:17920529; 10.1016/j.intimp.2007.07.019
58. P.Gao, X.Y.Zhou, Y.Yashiro-Ohtani, Y.F.Yang, N.Sugimoto, S.Ono, T.Nakanishi, S.Obika, T.Imanishi et al. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol 2003; 73:273-80; PMID:12554804; 10.1189/jlb.0602269
59. Y.Uekusa, W.G.Yu, T.Mukai, P.Gao, N.Yamaguchi, M.Murai, K.Matsushima, S.Obika, T.Imanishi et al. A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice. Cancer Res 2002; 62:3751-8; PMID:12097285
60. Y.F.Yang, T.Mukai, P.Gao, N.Yamaguchi, S.Ono, H.Iwaki, S.Obika, T.Imanishi, T.Tsujimura et al. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur J Immunol 2002; 32:2124-32; PMID:12209624; 10.1002/1521-4141(200208)32:8%3c2124::AID-IMMU2124%3e3.0.CO;2-S
61. M.Velasco-Velazquez, X.Jiao, M.De La Fuente, T.G.Pestell, A.Ertel, M.P.Lisanti, R.G.Pestell. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012; 72:3839-50; PMID:22637726; 10.1158/0008-5472.CAN-11-3917
62. S.S.Lieberman-Blum, H.B.Fung, J.C.Bandres. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 2008; 30:1228-50; PMID:18691983; 10.1016/S0149-2918(08)80048-3
63. S.Reagan-Shaw, M.Nihal, N.Ahmad. Dose translation from animal to human studies revisited. FASEB J 2008; 22:659-61; PMID:17942826; 10.1096/fj.07-9574LSF